Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Presentation TCT 2016

The Bioventrix SVR Procedure and Outcomes

Presenter: James E. Udelson, Petr Neuzil

October 31, 2016

News Industry News

BioVentrix Receives CE Marking Certification for Revivent TC™, the First Minimally Invasive Heart Failure Treatment to Restore the Left Ventricle

June 27, 2016

News Industry News

BioVentrix Announces Successful First-In-Man, Catheter-Based Endovascular Clinical Procedure

May 17, 2016

News Industry News

BioVentrix Announces Successful First-In-Man, Catheter-Based Endovascular Clinical Procedure with Revivent-TC™ System for Heart Failure Treatment

May 16, 2016

News Industry News

BioVentrix Announces 30th Clinical Case Milestone for Revivent-TC™ Technology

December 13, 2015

News Industry News

BioVentrix Announces Milestone Achievement of its First Interventional Heart Failure Procedure for LV Volume Reduction in a Pre-Clinical Mode

December 08, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

Presentation TCT 2015

BioVentrix: Description and Clinical Update

Presenter: Ileana L. Pina, James E. Udelson, Petr Neuzil

October 12, 2015

Presentation TVT 2015

Impact of Ventricular Reshaping on MR: From iCoapsys to BioVentrix

Presenter: Ted Feldman, Nicolo Piazza, Horst Sievert, Helge Möllmann

June 05, 2015

Presentation TCT 2013

Bioventrix

Presenter: Lon Annest

October 28, 2013

News Industry News

First BioVentrix Revivent® System Clinical Patients Sustain 39.6% Improvement in Heart Function at One Year

June 27, 2013

News Industry News

Updated ‘STICH’ study concludes that Surgical Ventricular Reconstruction (SVR) in conjunction with CABG decreased mortality by 64% in heart failure patients compared with CABG

January 27, 2013

Presentation TCT 2012

BioVentrix Minimally Invasive Reshaping of the Anterior Infarcted Heart

Presenter: Lon Annest

October 23, 2012

Advertisement

The Bioventrix SVR Procedure and Outcomes

BioVentrix Receives CE Marking Certification for Revivent TC™, the First Minimally Invasive Heart Failure Treatment to Restore the Left Ventricle

BioVentrix Announces Successful First-In-Man, Catheter-Based Endovascular Clinical Procedure

BioVentrix Announces Successful First-In-Man, Catheter-Based Endovascular Clinical Procedure with Revivent-TC™ System for Heart Failure Treatment

BioVentrix Announces 30th Clinical Case Milestone for Revivent-TC™ Technology

BioVentrix Announces Milestone Achievement of its First Interventional Heart Failure Procedure for LV Volume Reduction in a Pre-Clinical Mode

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

BioVentrix: Description and Clinical Update

Impact of Ventricular Reshaping on MR: From iCoapsys to BioVentrix

Bioventrix

First BioVentrix Revivent® System Clinical Patients Sustain 39.6% Improvement in Heart Function at One Year

Updated ‘STICH’ study concludes that Surgical Ventricular Reconstruction (SVR) in conjunction with CABG decreased mortality by 64% in heart failure patients compared with CABG

BioVentrix Minimally Invasive Reshaping of the Anterior Infarcted Heart

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content